Durect Shares Soar With Takeover Offer From Bausch Health

Dow Jones07-29

By Robb M. Stewart

Durect's shares saw a more than fourfold jump after agreeing to a deal to be acquired by Canadian pharmaceutical company Bausch Health for $63 million in cash upfront.

In morning trading, Durect shares were changing hands at $2.37, soaring from the previous day's close of 55 cents. Bausch was down 1.4% at C$9.32 in Toronto, widening the year-to-date fall to 20%.

Bausch said Tuesday it reached a definitive agreement under which it will pay $1.75 a share upfront for Durect. Two possible milestone payments totaling up to $350 million will be payable by Bausch if certain targets are reached before either the 10-year anniversary of the first commercial sales in the U.S. and the end of 2045.

The transaction, which is expected to close in the third quarter, remains conditioned on a majority of the outstanding shares of Durect being tendered to the offer.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

July 29, 2025 10:15 ET (14:15 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2555057874?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555057874","market":"sh","top_or_hot":-1,"title":"Durect Shares Soar With Takeover Offer From Bausch Health","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/DRRX\">Durect</a>'s shares saw a more than fourfold jump after agreeing to a deal to be acquired by Canadian pharmaceutical company Bausch Health for $63 million in cash upfront. \n</p>\n<p>\n  In morning trading, Durect shares were changing hands at $2.37, soaring from the previous day's close of 55 cents. Bausch was down 1.4% at C$9.32 in Toronto, widening the year-to-date fall to 20%. \n</p>\n<p>\n  Bausch said Tuesday it reached a definitive agreement under which it will pay $1.75 a share upfront for Durect. Two possible milestone payments totaling up to $350 million will be payable by Bausch if certain targets are reached before either the 10-year anniversary of the first commercial sales in the U.S. and the end of 2045. \n</p>\n<p>\n  The transaction, which is expected to close in the third quarter, remains conditioned on a majority of the outstanding shares of Durect being tendered to the offer. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 29, 2025 10:15 ET (14:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Durect Shares Soar With Takeover Offer From Bausch Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDurect Shares Soar With Takeover Offer From Bausch Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-29 22:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/DRRX\">Durect</a>'s shares saw a more than fourfold jump after agreeing to a deal to be acquired by Canadian pharmaceutical company Bausch Health for $63 million in cash upfront. \n</p>\n<p>\n  In morning trading, Durect shares were changing hands at $2.37, soaring from the previous day's close of 55 cents. Bausch was down 1.4% at C$9.32 in Toronto, widening the year-to-date fall to 20%. \n</p>\n<p>\n  Bausch said Tuesday it reached a definitive agreement under which it will pay $1.75 a share upfront for Durect. Two possible milestone payments totaling up to $350 million will be payable by Bausch if certain targets are reached before either the 10-year anniversary of the first commercial sales in the U.S. and the end of 2045. \n</p>\n<p>\n  The transaction, which is expected to close in the third quarter, remains conditioned on a majority of the outstanding shares of Durect being tendered to the offer. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 29, 2025 10:15 ET (14:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DRRX","symbol_name":"Durect Corporation","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2555057874","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555057874","pubTimestamp":1753798500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Durect's shares saw a more than fourfold jump after agreeing to a deal to be acquired by Canadian pharmaceutical company Bausch Health for $63 million in cash upfront.In morning trading, Durect shares were changing hands at $2.37, soaring from the previous day's close of 55 cents. Bausch was down 1.4% at C$9.32 in Toronto, widening the year-to-date fall to 20%.Bausch said Tuesday it reached a definitive agreement under which it will pay $1.75 a share upfront for Durect. Two possible milestone payments totaling up to $350 million will be payable by Bausch if certain targets are reached before either the 10-year anniversary of the first commercial sales in the U.S. and the end of 2045.The transaction, which is expected to close in the third quarter, remains conditioned on a majority of the outstanding shares of Durect being tendered to the offer.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DRRX":"Durect Corporation","BHC":"Bausch Health Companies Inc","BK4557":"大麻股","BK4007":"制药"},"translate_title":"Bausch Health提出收购要约，Durect股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHC":0.9,"DRRX":1},"content_text":"By Robb M. Stewart \n\n\n \n\n\nDurect's shares saw a more than fourfold jump after agreeing to a deal to be acquired by Canadian pharmaceutical company Bausch Health for $63 million in cash upfront. \n\n\n  In morning trading, Durect shares were changing hands at $2.37, soaring from the previous day's close of 55 cents. Bausch was down 1.4% at C$9.32 in Toronto, widening the year-to-date fall to 20%. \n\n\n  Bausch said Tuesday it reached a definitive agreement under which it will pay $1.75 a share upfront for Durect. Two possible milestone payments totaling up to $350 million will be payable by Bausch if certain targets are reached before either the 10-year anniversary of the first commercial sales in the U.S. and the end of 2045. \n\n\n  The transaction, which is expected to close in the third quarter, remains conditioned on a majority of the outstanding shares of Durect being tendered to the offer. \n\n\n \n\n\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 29, 2025 10:15 ET (14:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555057874","isCrawlerRequest":true}